title: The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer.
abstract: BACKGROUND
  The aim of this study is to evaluate the associations between vascular endothelial growth factor (VEGF) Single-nucleotide polymorphisms (SNPs) and clinical outcome in advanced gastric cancer patients treated with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX).
  
  
  METHODS
  Genomic DNA was isolated from whole blood, and six VEGF (-2578C/A, -2489C/T, -1498 T/C, -634 G/C, +936C/T, and +1612 G/A) gene polymorphisms were analyzed by PCR. Levels of serum VEGF were measured using enzyme-linked immunoassays.
  
  
  RESULTS
  Patients with G/G genotype for VEGF -634 G/C gene polymorphism showed a lower response rate (22.2%) than those with G/C or C/C genotype (32.3%, 51.1%; P = 0.034). Patients with the VEGF -634 G/C polymorphism G/C + C/C genotype had a longer progression free survival (PFS) of 4.9 months, compared with the PFS of 3.5 months for those with the G/G (P = 0.043, log-rank test). By multivariate analysis, this G/G genotype of VEGF -634 G/C polymorphism was identified as an independent prognostic factor (Hazard ratio 1.497, P = 0.017).
  
  
  CONCLUSIONS
  Our data suggest that G/G genotype of VEGF -634 G/C polymorphism is related to the higher serum levels of VEGF, and poor clinical outcome in advanced gastric cancer patients.
authors: Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
authors: Sung Yong
authors: SY
authors: Oh
authors: Hyuk-Chan
authors: HC
authors: Kwon
authors: Sung Hyun
authors: SH
authors: Kim
authors: Suee
authors: S
authors: Lee
authors: Ji Hyun
authors: JH
authors: Lee
authors: Jung-Ah
authors: JA
authors: Hwang
authors: Seung Hyun
authors: SH
authors: Hong
authors: Christian A
authors: CA
authors: Graves
authors: Kevin
authors: K
authors: Camphausen
authors: Hyo-Jin
authors: HJ
authors: Kim
authors: Yeon-Su
authors: YS
authors: Lee
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics*; D016009:Chi-Square Distribution; D018572:Disease-Free Survival; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D020022:Genetic Predisposition to Disease; D006801:Humans; D053208:Kaplan-Meier Estimate; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010641:Phenotype; D016133:Polymerase Chain Reaction; D020641:Polymorphism, Single Nucleotide; D016016:Proportional Hazards Models; D011446:Prospective Studies; D013274:Stomach Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome; D015854:Up-Regulation; D042461:Vascular Endothelial Growth Factor A / Q000097:blood / Q000235:genetics*; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D009944:Organoplatinum Compounds; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D002955:Leucovorin; D005472:Fluorouracil
references: Anticancer Res. 2011 Oct;31(10):3543-54
references: 21965776
references: Ann Oncol. 2007 Jun;18(6):1030-6
references: 17426061
references: Cytokine. 2000 Aug;12(8):1232-5
references: 10930302
references: Oncol Rep. 2009 Jul;22(1):127-36
references: 19513514
references: Anticancer Res. 2008 Mar-Apr;28(2B):1271-6
references: 18505065
references: Anticancer Res. 2007 Jul-Aug;27(4B):2535-9
references: 17695550
references: Cancer Res Treat. 2011 Mar;43(1):1-11
references: 21509157
references: J Clin Oncol. 2008 Oct 1;26(28):4672-8
references: 18824714
references: Cancer Res Treat. 2010 Mar;42(1):24-9
references: 20369048
references: Cancer. 1996 Mar 1;77(5):858-63
references: 8608475
references: Mol Endocrinol. 2001 Dec;15(12):2197-210
references: 11731620
references: Clin Cancer Res. 2008 Nov 15;14(22):7554-63
references: 19010874
references: Lancet Oncol. 2001 Nov;2(11):667-73
references: 11902537
references: Ann Oncol. 2007 Mar;18(3):504-9
references: 17322540
references: Acta Oncol. 2007;46(3):336-41
references: 17450469
references: Diabetes. 2002 May;51(5):1635-9
references: 11978667
references: Am J Clin Oncol. 2010 Jun;33(3):246-50
references: 19770628
references: J Clin Oncol. 2006 Jun 20;24(18):2903-9
references: 16782930
references: Mol Cancer Ther. 2009 Sep;8(9):2496-508
references: 19755511
references: Cancer. 2010 Mar 15;116(6):1446-53
references: 20108336
references: Endocr Rev. 1997 Feb;18(1):4-25
references: 9034784
references: Clin Cancer Res. 2008 Jan 1;14(1):62-6
references: 18172253
references: Oncol Rep. 2007 Nov;18(5):1155-63
references: 17914566
references: J Korean Med Sci. 2008 Jun;23(3):421-7
references: 18583877
references: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references: 15761078
references: Pharmacogenomics J. 2011 Jun;11(3):227-36
references: 20531372
references: Semin Oncol. 2002 Dec;29(6 Suppl 16):3-9
references: 12516032
references: J Surg Oncol. 2006 Dec 1;94(7):624-30
references: 17111394
references: Pharmacogenomics J. 2011 Feb;11(1):53-60
references: 20125120
references: J Clin Oncol. 1997 Feb;15(2):826-32
references: 9053510
references: Int J Colorectal Dis. 2011 Feb;26(2):143-51
references: 21188390